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Facial painAbstract Objective: The aim of this article is to review the mechanism of action, physiological
effects, and therapeutic applications of botulinum neurotoxins in the head and neck area.
Study design: An extensive literature search was performed using keywords. The resulting
articles were analyzed for relevance in four areas: overview on botulinum neurotoxins, the role
of botulinum neurotoxins in the management of salivary secretory disorders, the role of botulinum
neurotoxins in the management of facial pain, and the role of botulinum neurotoxins in head and
neck movement disorders. Institutional review board approval was not needed due the nature of the
study.
Results: Botulinum neurotoxin therapy was demonstrated to be a valuable alternative to
conventional medical therapy for many conditions affecting the head and neck area in terms of
morbidly, mortality, and patient satisfaction with treatment outcomes.
Conclusion: Botulinum neurotoxin therapy provides viable alternatives to traditional treatment
modalities for some conditions affecting the head and neck region that have neurological compo-
nents. This therapy can overcome some of the morbidities associated with conventional therapy.
4 A. Alshadwi et al.More research is needed to determine the ideal doses of botulinum neurotoxin to treat different dis-
eases affecting the head and neck regions.
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Botulinum Toxin interfere with the neuromuscular junction.
(Source: www.carolinafacialplasticsurgery.com)1. Overview on botulinum neurotoxins
The discovery of botulinum neurotoxin (BTX) in the late
19th century by Van Ermengem was a medical break-
through, as it unlocked the secret of a deadly disease at that
time––botulism. Van Ermengem’s publication in 1897 estab-
lished the foundation for research on botulism that led to
the food preservation measures we use today (Gunn, 1979;
van Ermengem, 1979; Erbguth and Naumann, 1999; Scott,
2004). Interest in BTXs increased rapidly in the 20th century
in response to the threat of biologic weapons during World
War II when American scientists were able to purify BTXs
for military use. In the aftermath of World War II, BTXs
were employed in the experimental medical ﬁeld. In 1973,
Scott et al. (1973) performed pioneering animal experiments
involving the injection of BTX into primate extraocular
muscles, and they reported the ability to safely paralyze a
given muscle. In 1977, human trials demonstrated that
injections of BTX into the extraocular muscle could be an
effective treatment for strabismus. As a result of this
research, the US Food and Drug Administration (FDA)
approved the use of BTX in 1989. In 2004, the FDA
released a draft reviewing the approved applications of
BTXs, which included strabismus, cervical dystonia, primary
axillary hyperhidrosis, and blepharo-spasm (Scott, 1980;
Neuenschwander et al., 2000; Blitzer and Sulica, 2001).
BTX is a polypeptide protoxin synthesized by Clostridium
botulinum, which is a Gram-positive, obligate anaerobic
bacterium. C. botulinum is classiﬁed immunologically into the
following distinct serotypes: A, B, C1, C2, D, E, F, and G.
BTX is synthesized as a single chain with a molecular weight
of approximately 150 kD (Setler, 2002; Thakker and Rubin,
2004). The ﬁnal weight of these multimeric complexes range
from 700 kD for BTX type B to 900 kD for BTX type A, lar-
gely reﬂecting the weight of added surface proteins (Simpson,
1979; Gonnering, 1993).
BTX interferes with the function of the neuromuscular
junction (NMJ) by inhibiting the release of acetylcholine
from presynaptic terminals. This process begins with the
binding of BTX to presynaptic receptors via the heavy chainmolecule followed by internalization of the toxin through
receptor-mediated endocytosis. Next, the light chain mole-
cule passes through the vesicle wall. Subsequently, BTX
cleaves a protein called SNAP-25, which is essential for
the docking and release of acetylcholine from vesicles within
nerve endings, hence inhibiting its release outside the cell
(Fig. 1). This mechanism explains how an intramuscular
injection of BTX produces partial chemical denervation of
the muscle, resulting in a localized reduction in muscle
activity or ‘‘paralysis’’ (Simpson, 1979; Gonnering, 1993;
Neuenschwander et al., 2000; Blitzer and Sulica, 2001;
Lam, 2003). Onset of paralysis occurs as rapidly as 6 h after
administration, whereas clinical effects are apparent within
24–72 h (Carruthers et al., 2003).
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attempts to overcome botulinum blockade of the NMJ. Recov-
ery may be a response to a growth factor secreted by the par-
alyzed muscle accessory terminals, which ‘‘sprout’’ from the
poisoned presynaptic axon and stimulate the development of
new NMJs. The primary nerve terminal recovers its full activ-
ity and reestablishes itself as the only functioning NMJ by
90 days after BTX administration. However, with repeated
exposure to BTX, this process becomes progressively longer.
Each vial of Botox contains 100 units (U) of C. botulinum
type A neurotoxin complex, 0.5 mg of albumin (human), and
0.9 mg of sodium chloride in a sterile, vacuum-dried form
without preservatives. One unit of Botox corresponds to the
calculated median intraperitoneal lethal dose required to kill
50% (LD50) of a group of 18–20 g female Swiss-Webster mice.
Commercial preparations of BTX available in the United
States include Botox (BTX type A, Allergan, Irvine, USA),
Myobloc (BTX type B, Solstice Neurosciences, Inc., San Fran-
cisco, USA), and Dysport (BTX type A, Ipsen Ltd., Maiden-
head, UK). In humans, the LD50 is estimated to be 40 U/kg
(2800 U for a 70 kg adult) (Vartanian and Dayan, 2003).
The preparation of freeze-dried BTX (type A) is stable for
2 y when refrigerated at 2–8 C. Reconstituted BTX (type A)
retains its clinical efﬁcacy for up to 6 weeks when stored at
4 C, yet the package insert recommends use of the entire vial
within 4 h when stored at 2–8 C. Others have reported that
BTX loses its clinical efﬁciency within 12 h despite refrigeration
(Gartlan and Hoffman, 1993). In contrast, BTX (type B) is
maintained in a liquid form and does not require reconstitution.
It retains its potency for 9 months at room temperature (25 C)
and for 3 y at refrigerated temperatures (2–8 C) (Lam, 2003).
A complete course of BTX treatment for every site in the
head and neck should not require more than 100–125 U of
BTX per session. Localized side effects include pain, edema,
ecchymosis at the site of the injections, headaches, dry mouth,
and mild malaise (Kessler et al., 1999; Lam, 2003). No reports
of severe life-threatening complications of BTX injections in
the head and neck have been published to date. According
to the Working Group on Civilian Biodefense, the estimated
human median lethal dose of BTX is 1.3–2.1 ng/kg when
injected intravenously or intramuscularly and 10–13 ng/kg
when inhaled (Arnon et al., 2001). However, localized adverse
consequences including unintended and transient muscle paral-
ysis have been occasionally noted from BTX injections of
higher doses (Blitzer and Sulica, 2001; Vartanian and Dayan,
2003). Moreover, approximately 5–10% of patients receiving
repetitive high doses of BTX (type A) develop antibotulinum
antibodies, which may contribute to resistance (Jankovic,
1994; Naumann et al., 1998). Noncosmetic application of
BTX typically requires higher doses, which may lead to unex-
pected complications (e.g. hoarseness, dry mouth, and dyspha-
gia). One study reported new-onset dysphagia after BTX
treatment of cervical dystonia in 33% of the patients
(Comella et al., 1992). Although no known drug reverses the
action of BTX, the use of 0.5% apraclonidine eye drops (iopi-
dine) has been reported to treat ptosis after BTX therapy of
the forehead by activating other muscles involved in maintain-
ing upper eyelid retraction (Scheinfeld, 2005). BTX could
potentially have drug interactions with medications (e.g., suc-
cinylcholine, aminoglycosides, D-penicillamine, and cyclo-
sporin) that alter neuromuscular transmission (Bucknall,
1977; Wang et al., 1984; Kadieva et al., 1992; Lam, 2003).2. BTXs in the management of salivary secretory disorders
Salivary secretory diseases constitute a true challenge to the
treating surgeon. These disorders may result from complica-
tions following major salivary gland surgery, oropharyngeal
cancer surgery (Ellies et al., 2004), or post-traumatic/iatrogenic
salivary sialoceles (Marchese-Ragona et al., 2005; Marchese-
Ragona et al., 2006). These diseases also include neurologic
drooling or sialorrhea, which are caused by either impaired
swallowing after head and neck oncological surgery or radia-
tion (Porta et al., 2001; Capaccio et al., 2004; Arnaud et al.,
2006; Capaccio et al., 2007). In these cases, BTX is used to
inhibit presynaptic acetylcholine release at the NMJs of sali-
vary glands by cleaving the soluble N-ethyl-maleimide–sensi-
tive factor attachment protein receptors, which are proteins
involved in the neuroexocytosis process (Sollner et al., 1993).
As a result, parasympathetic-dependent secretory function is
depressed, whereas the basal ﬂow rate is maintained by the
adrenergic pathway, thus avoiding the risk of xerostomia
(Ellies et al., 2004; Capaccio et al., 2008). Only a few clinical
studies have been published concerning Botox therapy in this
ﬁeld, and there is a lack of long-term follow-up reports.
Frey’s syndrome is named after Lucia Frey, a neurologist at
the University of Warsaw, who published a landmark paper on
the ‘‘syndrome du nerf auriculotemporal’’ in 1923 (Frey, 1923).
Frey’s syndrome is characterized by sweating and ﬂushing of
the facial skin during meals. The postulated etiology is an
aberrant dysregeneration of the sectioned parasympathetic
ﬁbers normally innervating the parotid gland. The traumatized
ﬁbers lose their parotid targets and regenerate to innervate the
vessels and sweat glands of the overlying skin. In order for this
aberrant dysregeneration to occur, the sympathetic ﬁbers to
these vessels and sweat glands have to be damaged, which is
a frequent event in either parotid surgery or penetrating
parotid trauma. The regular function of the parotid parasym-
pathetic ﬁbers is to increase salivary secretion during eating.
The activation following aberrant regeneration produces an
activation of new targets during meals, resulting in local vaso-
dilatation, known as ‘‘gustatory ﬂushing,’’ and localized sweat-
ing, known as ‘‘gustatory sweating.’’ This syndrome occurs
because both parasympathetic ﬁbers going to the parotid and
sympathetic ﬁbers going to the skin and sweat glands join
the auriculotemporal nerve, which is within the vicinity of
the surgical ﬁeld (Sato, 1977). In addition, the cholinergic
receptors on the sweat glands are muscarinic, predominantly
of the M3 subtype, and similar to that of the parasympathetic
salivary gland nerves, with acetylcholine as the main neuro-
transmitter (Matthews and Robinson, 1980; Vilches et al.,
1995). The treatment modalities proposed for gustatory sweat-
ing can be classiﬁed in ﬁve main groups: (1) external radiother-
apy, (2) local or systemic application of anticholinergic drugs,
(3) surgical section of some portion of the efferent neural arc,
(4) interposition of a subcutaneous barrier (fat or muscle), and
(5) injection of BTX in the involved skin.
The injection of BTX type A in the skin for the treatment of
gustatory sweating was proposed in 1995 (Drobik and
Laskawi, 1995; Vilches et al., 1995). Although there is not an
ideal protocol for using BTX in the treatment of Frey’s syn-
drome, Capaccio et al. (2008) developed a protocol with a
good clinical outcome. Each parotid gland receives 25–60 U
of Botox per treatment fractionated into 4 doses because the
gland is conventionally divided into anterior, posterior, upper,
Figure 2 This illustration demonstrates the areas of Botox
injection in the major salivary glands. The parotid is divided into
four portions each receives 10–15 U of Botox; were as the
submandibular gland divided into anterior and posterior haves
each receives no more than 10–20 U of Botox.
Table 1 Starting doses of Botox injections for masticatory
muscles.
Muscle botox units (U)*
Anterior digastric 10
Lateral pterygoid 15
Masseter 20
Temporalis 25
Medial pterygoid 10
* Doses reﬂect unilateral treatment.
6 A. Alshadwi et al.and lower quadrants, none of which receives more than 15 U
of Botox. All injections should be within the body of the gland,
and the injections should be performed under ultrasound guid-
ance. In cases of total parotidectomy, the injections should be
directed toward the affected skin area.
In cases of salivary secretory disorders associated with
hypersalivation or sialorrhea (e.g., neurologic drooling due
to Parkinson disease), the above protocol can be implemented,
and in addition, the submandibular gland should receive 10–
40 U of Botox fractionated into 2 doses of no more than
20 U. These doses should be administered anteriorly and pos-
teriorly within the parenchyma of the gland. The distance
between each injection should be about 1 cm, and the expected
effect of the drug should last for 4 months (Fig. 2).
3. BTXs in the management of facial pain and migraines
The facial anatomy is fairly complex, and different structures
can produce pain, so it is imperative for clinicians to identify
the precise source of pain to provide effective management.
Treatment of facial pain can be quite frustrating for both cli-
nicians and patients because most of these disorders involve
multiple components (e.g., somatic, neurogenic, psychogenic
components) that can be resistant to conventional medical or
behavioral therapy. The use of Botox therapy for the manage-
ment of facial pain has gained increasing attention in the few
past years (Cheshire et al., 1994; De Andres et al., 2003;
Kurtoglu et al., 2008).
It is unclear how BTX functions to decrease pain. There are
at least ﬁve hypothetical mechanisms through which BTX may
alter pain sensation: alterations in levels of muscle nociceptor
sensitizers (Hohmann and Herkenham, 1999), diminished c-
motor neuron activity (Donaldson et al., 1998), alterations in
acetylcholine levels at autonomic synapses, neuroplastic
changes in the central nervous system (Wheeler, 2004), and
possible alterations in levels of nonacetylcholine neurotrans-
mitters (Bengtsson et al., 1986).Temporomandibular disorders (TMD) are a variety of dis-
orders involving the temporomandibular joint, the soft tissue
structures within the joint, and the mastication muscles. The
most common type of painful TMD is myofacial pain, which
is characterized by diffuse pain in the mastication muscles,
along with muscle dysfunction and tightness. TMD affects
young adults between the ages of 20 and 40 y, and females
are affected more frequently than males. Approximately 25–
30% of the population will seek medical care for TMD during
their lifetimes (Lynch et al., 1994). In the majority of patients
with myofacial facial pain, the etiologic factors are muscular
spasticity and fatigue secondary to microtrauma from maloc-
clusion, bruxisms, hypermobility, external stressors, and indi-
vidual psychomotor behaviors (e.g., excessive gum chewing)
(Okeson, 1985). Because of its paralyzing effect, BTX therapy
is expected to decrease stresses on the TMJ and related tissues
and relieve the affected muscular component of TMD.
The technique for therapeutic Botox injections in the treat-
ment of myofascial pain applies the same basic principle as in
other applications. The injection is directed into the mass of
the offending muscle. The most common muscles patients
complain about are the temporalis muscle, masseter muscle,
and the lateral pterygoid muscle. In this section, we will discuss
the operative technique for injection into these muscles
(Table 1). Botox (25 U) is usually administered across the tem-
poralis muscle of one side with 1 cm between the injection sites.
The masseter muscle is a very strong rectangular muscle that
occupies the lateral aspect of the ramus of the mandible. By
creating a line from the corner of the ala of the nose to the tra-
gus of the ear, all injections into the masseter should be below
this line to avoid injection into the pterygoid fossa, which
could result in unwanted effects. The 20 U of Botox used in
the masseter should be distributed along the muscle mass
(Fig. 3). The lateral pterygoid muscle is a V-shaped muscle
with two distinct heads, which reside in the infratemporal
fossa. The ﬁrst step in the technique for injecting this muscle
involves placing the patient in a semi-reclined position with
his/her mouth slightly open and the mandible shifted to the
opposite side of the intended site of injection. Then the needle
is advanced around the tuberosity until it hits the lateral pter-
ygoid plate, and 10 U of Botox is deposited. Next, the needle is
redirected superiorly to hit the infratemporal crest of the
greater wing of the sphenoid where an additional 10 U of
Botox is injected after aspiration (Mendes and Upton, 2009).
Migraine is a debilitating headache disorder that affects
approximately 15% of the population and is among the top
20 causes for disability as ranked by the World Health Orga-
nization. The clinical diagnosis of migraine is based on the
International Classiﬁcation of Headache Disorders (ICDH-2)
Figure 3 This illustration demonstrates the proposed locations
of Botox injection for the temporalis and masseter muscles.
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ﬁve), untreated or unsuccessfully treated headache with a
duration 4–72 h, and at least two of the following pain charac-
teristics: unilateral, pulsating, moderate to severe intensity,
and aggravated by routine physical activity. In addition, they
are associated with at least one of the following: nausea/vom-
iting, photophobia, or phonophobia. Moreover, all other
forms of headache must be excluded. There are migraines with
and without aura, and those with aura account for 80% of
migraines. The associated aura can include various reversible
visual or sensory symptoms, or it less commonly includes
speech or other motor symptoms. Chronic migraine and epi-
sodic migraine exist along the spectrum of migraine disorders,
but they are distinct clinical entities. Compared to episodic
migraine, chronic migraine causes higher levels of individual
and social burden because the sufferers are more disabled by
their condition and have a reduced quality of life (Katsarava
et al., 2012). Episodic migraine sufferers have up to 14 head-
aches per month, whereas chronic migraine sufferers have 15
or more headaches per month. The possibility of episodic
migraine transitioning to chronic migraine is approximately
2.5% per year. On the other hand, chronic migraines become
episodic approximately 25% of the time (Bigal et al., 2008;
Manack et al., 2011).
BTX type A was approved by the FDA for the treatment of
chronic migraines in 2010, and it is the only prophylactic ther-
apy speciﬁcally for chronic migraines (Durham and Cady,
2011). The mechanism by which BTX type A reduces migraine
frequency and intensity is not completely understood. BTX is
thought to inhibit overactive motor neurons and hyperexcit-
able sensory neurons and suppress peripheral and central
sensitization of trigeminal sensory nerves around muscle
trigger points. BTX is most effective when injected into an
active trigger point or at sites of compression of a branch of
the trigeminal nerve. These sites of anatomic compression havebeen identiﬁed through clinical experience as well as through
anatomic dissection. Compression can be related to facial
impingement, muscle contraction when there is an intramuscu-
lar component to the nerve, as well as blood vessel impinge-
ment of the nerve. The supratrochlear and supraorbital
nerves run through the corrugator supercilii, and chronic mus-
cle contraction can result in muscle impingement and trigger
migraines (Diener et al., 2014; Ashkenazi and Blumenfeld,
2013).
The Phase III Research Evaluating Migraine Prophylaxis
Therapy (PREEMPT) trials performed an in-depth analysis
on injection sites and techniques. Frontal migraines are the
most common type of migraines; therefore, injection of 35–
40 U BTX in the frontalis, corrugator, and procerus is the
most common injection technique. Temporal migraines are
the second most common type of migraines, and treatment
with 20–25 U BTX per side into multiple trigger points, partic-
ularly at the anterior aspect, is recommended. The back of the
neck is frequently reported to be a focus of pain. To treat the
splenius capitis and semispinalis muscles, they are injected with
20–30 U BTX, but identiﬁcation of these speciﬁc muscles is not
feasible. Therefore, the best method of injection is in the upper
neck (cervical paraspinal muscles) at the base of the skull
1.5 cm inferior and lateral to the occipital protuberance. The
occipitalis is another site of initiation of migraines, and can
be treated with injection of 10–20 U BTX on both sides of
and just superior to the occipital protuberance (Aurora
et al., 2010; Diener et al., 2014).
Trigeminal neuralgia is an excruciating, debilitating orofa-
cial illness, also known as tic douloureux, owing to the facial
expression or ﬂinch that often accompanies the painful
episode. It is a rare disorder, with an overall incidence of 3–
5 persons per 100,000 (with an increased risk in the elderly
where the incidence increases two to threefold to 6–12 persons
per 100,000) (Katusic et al., 1990). The pain is described as
stabbing, shooting, electric shock-like pain lasting seconds to
minutes (Table 2). Most times the patient is aware of the trig-
ger of the pain, such as a light touch to an intra- or extraoral
region, or a facial or tongue movement. The pain is almost
always unilateral and occurs nearly equally in the maxillary
and mandibular trigeminal divisions, and less commonly in
the ophthalmic division (Katusic et al., 1991; MacDonald
et al., 2000). Treatment modalities for trigeminal neuralgia
can be divided into pharmacological (e.g., carbamazepine, bac-
lofen, and pimozide) and surgical (e.g., glycerol rhizotomy,
microvascular decompression, and stereotactic radiosurgery).
Surgical treatment should be considered only when pharmaco-
therapy fails. Although some surgeons believe that there is a
risk of the patient developing more refractory or atypical tri-
geminal neuralgia if deﬁnitive intervention is excessively
delayed, medical options should be exhausted prior to surgical
intervention (Bowsher et al., 1997; Zakrzewska and Patsalos,
2002). The aim of BTX injections in these cases is to paralyze
the trigger points. A recent review by Manolopoulos et al.
(2008) demonstrated the efﬁcacy of Botox injections when
compared to local anesthesia injections. Two randomized clin-
ical trials showed that BTX type A injections were as efﬁcient
as topical anesthetics (bupivacaine 0.5%, lidocaine 0.5%) in
terms of the duration and magnitude of pain relief, function,
and quality of life, but BTX was less cost effective (Graboski
et al., 2005; Kamanli et al., 2005). However, two Cochrane
reviews did not provide conclusive evidence that BTX
Table 2 International Headache Society Diagnostic Criteria for Trigeminal Neuralgia.
Description of clinical features
Unilateral
Brief electric-shock like pain
Abrupt onset, abrupt termination (of pain paroxysm)
Evoked by trivial stimuli, but also occurs spontaneously
Trigger area
Remissions
Diagnostic criteria
Paroxysmal attacks of pain lasting from a fraction of a second to 2 min, aﬀecting one or more divisions of the trigeminal nerve and fulﬁlling
criteria B and C
Pain has at least one of the following characteristics:
Intense, sharp, superﬁcial or stabbing
Precipitated from trigger areas or by trigger factors
Attacks are stereotyped in the individual patient
There is no clinically evident neurological deﬁcit
Not attributed to another disorder
8 A. Alshadwi et al.injections are more effective than a placebo when used to treat
bilateral benign masseteric hypertrophy and trigger points in
myofacial pain syndrome. These results emphasize the need
for well-designed, randomized, controlled, clinical trials
(Al-Muharraqi et al., 2009; Soares et al., 2012).
Head and neck cancer survivors represent another category
of facial pain patients, whether they underwent surgical or
radiation treatment.
In 1986, Haubrich (1986) described ﬁrst-bite syndrome
(FBS). Typically, FBS patients report excruciating pain in
the parotid region only after the ﬁrst bite of a meal, hence
the name. The pain improves with subsequent masticatory
movements during that meal, but invariably returns to the
excruciating level at the ﬁrst bite of the next meal (Chiu
et al., 2002). The cause of FBS is largely unknown, but
Netterville et al. (1998) proposed that FBS is caused by the loss
of sympathetic innervation to the parotid gland with
subsequent hypersensitivity of myoepithelial cells to parasym-
pathetic neurotransmitters. This hypersensitivity is thought to
elicit a maximal contraction of myoepithelial cells during the
ﬁrst bite of a meal that subsides with continued masticatory
action. The concept that pain is elicited ultimately by myoep-
ithelial contraction led to the hypothesis that paralysis of these
myoepithelial ﬁlaments with BTX may relieve FBS symptoms.
In 2008 Ali et al. (2008) reported the ﬁrst documented use of
BTX in the treatment of FBS, thereby adding another applica-
tion of Botox in the medical ﬁeld. The operative procedure
involves placing the patient in supine position and inﬁltrating
the area some local anesthetic. The area where the patient feels
the most intense pain is marked preoperatively. The patient
receives an injection of 40–60 U of Botox in the parotid region.
It is recommended that the injection be delivered under ultra-
sound guidance. It may require 24–48 h for the Botox to
become effective. The effect of Botox is unpredictable, and
when it wears off varies from one individual to another.
4. BTXs in head and neck movement disorders
Head and neck movement disorders encompass a variety of
clinical manifestations. This wide spectrum of diseases is a
diagnostic enigma for the treating physicians and a socially
debilitating illness for the affected individuals. Dyskinesia isdeﬁned as abnormal involuntary movements that primarily
affect the extremities, trunk, or jaws and occur as a manifesta-
tion of an underlying disease process. Dyskinesia is also a
relatively common manifestation of basal ganglia diseases. In
contrast, dystonia is deﬁned as a persistent attitude or posture
due to contraction of agonist and antagonist muscles of the
affected organ or system. Dystonia can be focal, multifocal,
or generalized (de Carvalho Aguiar and Ozelius, 2002; Lee,
2007).
Oromandibular dystonia (OD) represents a focal dystonia
whereby repetitive or sustained spasms of the masticatory,
facial, or lingual muscles result in involuntary and possibly
painful jaw movements (Balasubramaniam et al., 2008). The
discovery of this condition is attributed to the French neurol-
ogist Henry Meige in 1910. Currently OD affects approxi-
mately 6.9 in 100,000 persons in the United States. It affects
women more commonly than men (2:1), with an average age
of onset between 30 and 50 y (Tan and Jankovic, 1999;
Blanchet et al., 2005).
The clinical presentation of OD can be quite variable
depending on the affected muscles. Chewing, speech, swallow-
ing, and facial expression can be affected in OD, which can
cause considerable functional disability. Oral trauma includes
rapid wear or early loss of teeth from persistent grinding,
and biting of the tongue may occur especially on the affected
side (Lee, 2007). Treatment strategies vary and are most effec-
tive when focused on treating the etiologic factor. It is classi-
cally managed by medication, BTX, local anesthetic blocks,
dental appliances, behavioral modiﬁcation, psychological sup-
port, and denervation procedures (Fahn and Jankovic, 1984;
Jankovic and Orman, 1987; Goldman and Comella, 2003;
Balash and Giladi, 2004). BTX has been shown to be clinically
superior to medical therapy, particularly in the treatment of
focal dystonias (Dutton, 1996; Tan and Jankovic, 2000). Injec-
tion of BTX type A into the muscles of the ﬂoor of the mouth,
the muscles of mastication, and the extrinsic muscles of the
tongue yield great improvement in this subtype of dystonia
by paralyzing the hyperactive dysfunctional group of muscles.
However, a recent Cochrane review showed no signiﬁcant dif-
ference in pain reduction at four weeks between those who
received BTX for subacute and chronic neck pain and those
who received placebo injections (Langevin et al., 2011).
Therapeutic applications of botulinum neurotoxins in head and neck disorders 95. Conclusions
The potential applications of BTXs extend beyond facial
cosmetic surgery. BTX therapy is a superior treatment
modality for a number of conditions when compared to
pharmacotherapy or surgical intervention in terms of morbid-
ity and mortality. These conditions include salivary secretory
disorders, facial pain, and head and neck movement disorders.
Although its use seems relatively easy, it is of utmost impor-
tance to obtain sound knowledge of the agent, its mechanism
of action, the pathophysiology of the disease, and the underly-
ing anatomy before one can incorporate this modality into his
or her practice.
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